June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Posterior polymorphous corneal dystrophy: Transcriptomic impact of OVOL2 and GRHL2 overexpression on corneal endothelial cells
Author Affiliations & Notes
  • Doug Chung
    Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • JooYeon Jung
    Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Marco Morselli
    University of California, Los Angeles, California, United States
  • Matteo Pellegrini
    University of California, Los Angeles, California, United States
  • Anthony J Aldave
    Ophthalmology, Jules Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Doug Chung, None; JooYeon Jung, None; Marco Morselli, None; Matteo Pellegrini, None; Anthony Aldave, None
  • Footnotes
    Support  Knights Templar Eye Foundation (KTEF) Career Starter Grant, UCLA Academic Senate Faculty Research Grant (FRG)
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1450. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Doug Chung, JooYeon Jung, Marco Morselli, Matteo Pellegrini, Anthony J Aldave; Posterior polymorphous corneal dystrophy: Transcriptomic impact of OVOL2 and GRHL2 overexpression on corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1450.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mutations in the promoter regions of the ovo like zinc finger 2 (OVOL2) and grainyhead like transcription factor 2 (GRHL2) genes are associated with posterior polymorphous corneal dystrophy (PPCD), an inherited disorder affecting the corneal endothelium, and have been demonstrated to be associated with ectopic expression of their respective gene. To determine the impact of OVOL2 and GRHL2 overexpression on the transcriptome of corneal endothelial cells, RNA-sequencing analysis was performed on primary human corneal endothelial cells transduced with lentivirus carrying either OVOL2 or GRHL2 overexpression vectors.

Methods : Lentiviruses containing OVOL2, GRHL2, or empty (as a control) overexpression constructs were generated, characterized, and then transduced into primary human corneal endothelial cells (pHCEnC). Total RNA and protein lysates were isolated from transduced pHCEnC. Western blot was performed to confirm overexpression of OVOL2 and GRHL2. RNA sequencing and transcriptomic analyses were performed, including differential gene expression, gene ontology (GO) enrichment, and canonical pathway analyses.

Results : OVOL2 overexpression in pHCEnC led to a total of 576 differentially expressed genes (DEG) (|fold-change| ≥ 2, q-value ≤ 0.05, min group expression ≥1 RPKM), with 388 upregulated and 188 downregulated genes, compared to controls. Additionally, OVOL2 overexpression in pHCEnC led to a -2.17 fold-change in ZEB1. GRHL2 overexpression in pHCEnC caused differential expression of 443 genes, with 225 upregulated and 218 downregulated genes, compared to controls. Overexpression of GRHL2 caused a fold-change of -1.46 in ZEB1. In both OVOL2 and GRHL2 overexpression, gene ontology and canonical pathway analyses identified cell adhesion, cell signaling, and immune response pathways to be in significantly impacted.

Conclusions : Overexpression of either OVOL2 or GRHL2 caused the downregulation of ZEB1 in human corneal endothelial cells, which supports the hypothesis that PPCD-associated OVOL2 and GRHL2 promoter mutations lead to PPCD by inducing ectopic expression of OVOL2 and GRHL2, respectively, and subsequently repressing the expression of ZEB1, a gene well-established to be associated with PPCD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×